These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date Terminated 2007-005980-83 MULTICENTRIC, PERSPECTIVE, RANDOMIZED TRIAL TO ASSESS THE INTRAOPERATIVE USE OF HYPERTHERMIC CHEMOTHERAPY IN LOCALLY ADVANCED NON SMALL CELL LUNG CANCER. COMPARISON BETWEEN LOCO-REGIONAL + SYSTEMIC CH... bad-data
Ongoing 2008-002715-40 NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY not-yet-due
Ongoing 2008-003316-36 NON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA not-yet-due
Completed, but no date 2009-017151-97 PHASE II STUDY OF SECOND LINE TREATMENT WITH WEEKLY NON-PEGILATE LIPOSOMIAL DOXORUBICIN IN METASTATIC GASTRIC CARCINOMA bad-data
Completed, but no date Terminated 2010-019726-14 SORAFENIB IN ELDERLY PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (SERCC STIDY). IMPACT OF ADVERSE EVENTS MANAGEMENT IN ELDERLY mRCC PATIENTS TREATED WITH SORAFENIB. bad-data
Ongoing 2010-023602-12 A FEASIBILITY STUDY EVALUATING THE EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR (HCC) CARCINOMA AND HIV INFECTION TREATED WITH HAART REGIMENS not-yet-due
Ongoing 2011-001720-37 Multi-centre, phase II, single arm study of the docetaxel, oxaliplatin, capecitabine (DOC) combination in untreated patients with advanced or metastatic gastric cancer not-yet-due
Ongoing 2011-005638-20 Phase III randomized trial of preoperative radiotherapy with an integrated simultaneous boost IMRT-IGRT) versus chemoradiotherapy for T3-4 rectal cancer not-yet-due
Ongoing 2012-002469-37 Phase II clinical study on the efficacy and safety of procedural analgesia of oral transmucosal fentanyl citrate in oncologic patients eligible to permanent central venous catheter not-yet-due